Source-grounded facts extracted from Enovis CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Enovis CORP shareholders approved Approve an amendment to the Enovis Corporation 2020 Omnibus Incentive Plan at the 2026-05-19 meeting.
“Proposal 4- Approve an amendment to the Enovis Corporation 2020 Omnibus Incentive Plan: The Company’s stockholders approved an amendment to the Enovis Corporation 2020 Omnibus Incentive Plan. The votes regarding this proposal were as follows: For Against Abstain Broker Non-Votes 50,391,554 1,295,073 92,212 2,032,985”
Enovis CORP shareholders approved Advisory vote on the executive compensation of the named executive officers at the 2026-05-19 meeting.
“Proposal 3- Advisory vote on the executive compensation of the named executive officers: The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: For Against Abstain Broker Non-Votes 49,531,111 2,175,335 72,393 2,032,985”
Enovis CORP shareholders approved Ratification of appointment of independent registered accounting firm at the 2026-05-19 meeting.
“Proposal 2 - Ratification of appointment of independent registered accounting firm: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The votes regarding this proposal were as follows: For Against Abstain 52,862,698 927,580 21,546”
Enovis CORP shareholders approved Election of Directors at the 2026-05-19 meeting.
“Proposal 1- Election of Directors: The Company’s stockholders elected ten directors to the Board (to hold office until the next annual meeting of stockholders and until their respective successors are elected and qualified). The votes regarding this proposal were as follows: Nominee For Against Abstain Broker Non-Votes Barbara W. Bodem 51,537,774 226,376 14,689 2,032,985 Liam J. Kelly 51,552,655 213,001 13,183 2,032,985 Angela S. Lalor 51,269,131 495,519 14,189 2,032,985 Damien McDonald 51,222,667 545,650 10,522 2,032,985 Philip A. Okala 51,540,973 223,651 14,215 2,032,985 Christine Ortiz 51,552,061 207,769 19,009 2,032,985 A. Clayton Perfall 50,959,268 805,763 13,808 2,032,985 Brady Shirley 50,994,745 773,196 10,898 2,032,985 Rajiv Vinnakota 51,206,665 557,399 14,775 2,032,985 Sharon Wienbar 51,553,287 209,586 15,966 2,032,985”
Enovis CORP reported first quarter ended April 3, 2026 results: revenue $589 million, net income $8 million, EPS $0.89. Guidance reaffirmed.
“Enovis’ first-quarter net sales of $589 million grew 5% on a reported basis and 3% on an organic basis from the same quarter in 2025.”
Enovis CORP amended Amendment No. 3 (the "Third Amendment") with JPMorgan Chase Bank, N.A., as administrative agent (effective 2025-12-08).
“On December 8, 2025, Enovis Corporation, a Delaware corporation (the “Company”), entered into Amendment No. 3 (the “Third Amendment”) to the Credit Agreement, dated April 4, 2022”
Enovis CORP amended credit facility of revolving credit facility of up to $1.1 billion and a term loan facility of $700.0 million with JPMorgan Chase Bank, N.A. at reduced the applicable margin for borrowings if the Total Leverage Ratio is less maturing December 8, 2030.
“lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as administrative agent. The Amended Credit Agreement provides for a revolving credit facility of up to $1.1 billion (the “Revolving Facility” and the loans thereunder, the “Revolving Loans”) and a term loan facility of $700.0 million (the “Term Loan Facility” and the loans thereunder, the”
Sharon Wienbar was appointed as independent Chair of the Board at Enovis CORP.
“the Board has (i) appointed Sharon Wienbar, who has served as the Lead Independent Director of the Board since May 2023, to serve as independent Chair of the Board”
Matthew L. Trerotola departed as Chief Executive Officer at Enovis CORP.
“Matthew L. Trerotola, the Company’s current CEO, will retire from such role as of the Appointment Date”
Damien McDonald was appointed as member of the Board at Enovis CORP.
“appointed Mr. McDonald as a member of the Board to fill the vacancy resulting from Mr. Trerotola’s retirement from the Board.”
Damien McDonald was appointed as Chief Executive Officer at Enovis CORP.
“the Board of Directors of the Company (the “Board”) has appointed Damien McDonald as Chief Executive Officer (“CEO”) of the Company, effective as of May 12, 2025”
Matthew L. Trerotola changed role as Chief Executive Officer at Enovis CORP.
“As previously announced by Enovis Corporation (the “Company”), on February 25, 2025, Matthew L. Trerotola notified the Board of Directors (the “Board”) of the Company of his intention to retire from his current position as Chief Executive Officer (“CEO”) of the Company, effective upon his successor being appointed by the Board and assuming the position as CEO of the Company (the “Appointment Date”).”
Matthew L. Trerotola departed as Chief Executive Officer at Enovis CORP.
“On February 25, 2025, Matthew L. Trerotola notified the Board of Directors (the “Board”) of Enovis Corporation (the “Company”) of his intention to retire from his current position as Chief Executive Officer (“CEO”) of the Company, effective upon his successor being appointed by the Board and assuming the position as CEO of the Company.”
Enovis CORP reported the first quarter ended March 29, 2024 results: revenue $516 million, net income net loss from continuing operations of $72 million, EPS net loss from continuing operations of $1.32 per share and adjusted earnings per diluted share of $0.50. Guidance raised.
“will host an investor conference call and live webcast to discuss these results today at 8:00 am ET. First Quarter 2024 Financial Results Enovis’ first-quarter net sales of $516 million grew 27% on a reported basis and 5% on a proforma basis from the same quarter in 2023. First-quarter results reflect continued execution in P&R, strong growth in Recon, and the”
Enovis CORP reported financial results for fourth quarter and fiscal year ended December 31, 2023.
“On February 22, 2024, the Company issued a press release reporting financial results for the year ended ended December 31, 2023.”
Enovis CORP completed an acquisition involving Emil Holding II S.à r.l (closed 2024-01-03).
“on January 3, 2024, Enovis Corporation (the “Company” or “Enovis”) completed its previously announced acquisition of LimaCorporate S.p.A. (“Lima”) from Emil Holding II S.à r.l (“Seller”).”
Enovis CORP completed an acquisition involving Emil Holding II S.à r.l for cash consideration of approximately €726.8 million, which included the repayment of certain Lima indebtedness, transfer taxes and notarial fees, and 1,942,686 s (closed 2024-01-03).
““Purchase Agreement”) with the Seller, the Company acquired all of the issued and outstanding share capital of Lima from the Seller for (i) cash consideration of approximately €726.8 million, which included the repayment of certain Lima indebtedness, transfer taxes and notarial fees, and (ii) 1,942,686 shares of Enovis common stock, par value $0.001 per share (the”
Brady R. Shirley changed role as President and Chief Operating Officer at Enovis CORP.
“Effective as of April 1, 2024, Mr. Shirley will step down from his current position as President and Chief Operating Officer and assume the role of Executive Advisor, focusing on ensuring the successful integration of the Company’s pending acquisition of LimaCorporate S.p.A. and mentoring the Company’s business leaders until his eventual transition to retirement”
Enovis CORP updated its third quarter ended September 29, 2023 guidance (raised).
“On November 7, 2023, the Company issued a press release reporting financial results for the third quarter ended ended September 29, 2023.”
Enovis CORP incurred convertible notes of $460 million with UBS Securities LLC and J.P. Morgan Securities LLC at 3.875% per year maturing October 15, 2028.
“On October 24, 2023, Enovis Corporation, a Delaware corporation (the “Company”) sold to UBS Securities LLC and J.P. Morgan Securities LLC, as representatives (the “Representatives”) of the several initial purchasers (the “Initial Purchasers”), and the Initial Purchasers purchased from the Company, $460 million aggregate principal amount of the Company’s 3.875% Convertible Senior Notes due 2028”
Enovis CORP amended Amendment No. 1.
“Amendment No. 1 (the “Amendment”) to the credit agreement, dated as of April 4, 2022 (as amended by the Amendment, the “Credit Agreement”), by and among, amongst others, the Company, as the lead borrower, certain U.S. subsidiaries of the Company identified therein, as guarantors, each of the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent”
Enovis CORP entered into Indenture with U.S. Bank Trust Company, National Association valued at $460 million (effective 2023-10-24).
“the Company entered into an Indenture, dated October 24, 2023 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee”
Enovis CORP reported the third quarter ended September 29, 2023 results: revenue $414 and $418 million.
“On October 19, 2023, Enovis Corporation (the “Company”) released the following preliminary information about its performance for the third quarter ended September 29, 2023. Revenues for the three months ended September 29, 2023 are expected to be between $414 and $418 million”
Enovis CORP entered into Commitment Letter with JPMorgan Chase Bank, N.A., UBS AG Stamford Branch, UBS Securities LLC valued at $800 million senior bridge facility and $400 million senior term loan facility (effective 2023-09-22).
“In connection with entering into the Purchase Agreement, on September 22, 2023, the Company entered into a commitment letter (the “Commitment Letter”) with JPMorgan Chase Bank, N.A. (“JPMorgan”), UBS AG Stamford Branch (“UBS AG”), and UBS Securities LLC (“UBS Securities”), pursuant to which JPMorgan and UBS AG agreed to provide a new $800 million senior bridge facility (the “Bridge Facility”) for financing the Acquisition.”
Enovis CORP entered into Share Purchase Agreement with Emil Holding II S.à r.l. valued at Enterprise value of approximately €800 million: ~€700 million cash plus 1,942,686 shares of Enovis c (effective 2023-09-22).
“On September 22, 2023, Enovis Corporation (the “Company”) entered into a definitive agreement to acquire LimaCorporate S.p.A. (“Lima”), a privately held global orthopedic company focused on restoring motion through digital innovation and customized hardware.”
Enovis CORP reported the second quarter ended June 30, 2023 results: revenue $429 million, EPS net loss from continuing operations of $0.27 per share. Guidance raised.
“Enovis’ second quarter net sales of $429 million grew 8% from the same quarter a year ago, including 9% organic sales per day growth, and reflecting a 0.7% sales days headwind which was slightly offset by currency and recent acquisitions.”
Enovis CORP shareholders approved Approve the Enovis Corporation 2023 Non-Qualified Stock Purchase Plan at the 2023-05-16 meeting.
“Proposal 5- Approve the Enovis Corporation 2023 Non-Qualified Stock Purchase Plan: The Company’s stockholders approved the Enovis Corporation 2023 Non-Qualified Stock Purchase Plan.”
Enovis CORP shareholders approved Advisory vote on the frequency of future advisory votes on the executive compensation of the named executive officers at the 2023-05-16 meeting.
“Proposal 4 - Advisory vote on the frequency of future advisory votes on the executive compensation of the named executive officers: The Company’s stockholders voted, on a non-binding advisory basis, on the frequency of future advisory votes on the compensation of the Company’s named executive officers.”
Enovis CORP shareholders approved Advisory vote on the executive compensation of the named executive officers at the 2023-05-16 meeting.
“Proposal 3- Advisory vote on the executive compensation of the named executive officers: The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers.”
Enovis CORP shareholders approved Ratification of appointment of independent registered accounting firm at the 2023-05-16 meeting.
“Proposal 2 - Ratification of appointment of independent registered accounting firm: The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.”
Enovis CORP shareholders approved Election of Directors at the 2023-05-16 meeting.
“Proposal 1- Election of Directors: The Company’s stockholders elected ten directors to the Board (to hold office until the next annual meeting of stockholders and until their respective successors are elected and qualified).”
Enovis CORP reported first quarter ended March 31, 2023 results: revenue $406 million, net income net loss from continuing operations of $23 million, EPS adjusted earnings per share of $0.44. Guidance raised.
“will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2023 Financial Results Enovis’ first quarter net sales of $406 million grew 8% from the prior year quarter, including 9% organic growth and a 1.5% currency headwind. Sales in the Reconstructive segment grew 19%, both as reported and organically, and”
Sharon Wienbar was appointed as Lead Independent Director at Enovis CORP.
“independent director Sharon Wienbar will become Lead Independent Director”
Matthew L. Trerotola was appointed as Chair of the Board at Enovis CORP.
“Matthew L. Trerotola, the Company’s Chief Executive Officer and a current director, will become Chair of the Board”
Mitchell P. Rales departed as Chair of the Board at Enovis CORP.
“Mitchell P. Rales notified the Board of Directors (the “Board”) of Enovis Corporation (the “Company”) that he will not stand for re-election as a director and will retire from the Board upon the expiration of his term at the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”) on May 16, 2023.”
Enovis CORP reported the 2022 fiscal year results: revenue $1.6 billion, net income net loss from continuing operations of $38 million, or $0.25 per diluted share, EPS $2.27. Guidance initiated.
“segment grew 12%, and 14% on an organic basis, and its Prevention and Recovery segment declined 2% with 1% organic growth. For the 2022 fiscal year, net sales grew 10% to $1.6 billion, with organic growth of 6%. Enovis also reported a fourth quarter operating loss of $28 million or 6.9% of sales, and adjusted EBITDA of $75 million, or 18.3% of sales, an”
Enovis CORP reported the fourth quarter ended December 31, 2022 results: revenue $409 million, net income net loss from continuing operations of $55 million, or $0.71 per diluted share, EPS $0.72.
“• Completed first year as independent Med Tech growth company with sales growth of 10%, organic growth of 6% and EBITDA margin expansion • Grew fourth quarter sales 2% to $409 million, with 5% organic growth over the prior year quarter, and double-digit growth performance in its Reconstructive segment • Reported a fourth quarter net loss from continuing”
Phillip Benjamin (Ben) Berry was appointed as Chief Financial Officer at Enovis CORP.
“the Company’s board of directors appointed Phillip Benjamin (Ben) Berry as the Company’s new Chief Financial Officer and principal financial officer, effective as of January 1, 2023”
Christopher M. Hix retired as Executive Vice President and Chief Financial Officer at Enovis CORP.
“Christopher M. Hix retired from his position as the Company’s Executive Vice President and Chief Financial Officer and ceased to serve as the Company’s principal financial officer on December 31, 2022”
Enovis CORP: Amended and restated bylaws to update stockholder meeting procedures, align with Delaware law, adopt universal proxy rules, and make technical changes (effective 2022-12-13).
“On December 13, 2022, the Board of Directors of Enovis Corporation (the “Company”) adopted and approved amended and restated bylaws (the “Amended and Restated Bylaws”), effective as of such date.”
Enovis CORP reported third quarter 2022 results: revenue $384 million, net income $(66) million, EPS $(1.22) per diluted share.
“Enovis’ third quarter net sales of $384 million were 7% higher than the prior year third quarter on both reported and organic bases. Enovis Reconstructive segment revenue of $127 million reflected 15% organic growth, and its Prevention and Recovery segment revenue of $257 million reflected 4% organic growth. The Company reported third quarter 2022 net loss from continuing operations of $(66) million, or $(1.22) per diluted share”
Phillip Benjamin (Ben) Berry was appointed as Chief Financial Officer and principal financial officer at Enovis CORP.
“the Company expects to appoint Phillip Benjamin (Ben) Berry, the current chief financial officer of the Company’s business units, as its new chief financial officer and principal financial officer.”
Christopher M. Hix retired as Executive Vice President and Chief Financial Officer at Enovis CORP.
“Christopher M. Hix will retire from his position as the Company’s Executive Vice President and Chief Financial Officer and cease to serve as the Company’s principal financial officer on December 31, 2022.”
Brady R. Shirley was appointed as Director at Enovis CORP.
“In connection with the vacancies created by the director resignations and retirement, on April 4, 2022, effective upon consummation of the Separation, each of Barbara W. Bodem, Angela S. Lalor, Dr. Christine Ortiz and Brady R. Shirley were appointed by the Board to serve as directors of the Company.”
Dr. Christine Ortiz was appointed as Director at Enovis CORP.
“In connection with the vacancies created by the director resignations and retirement, on April 4, 2022, effective upon consummation of the Separation, each of Barbara W. Bodem, Angela S. Lalor, Dr. Christine Ortiz and Brady R. Shirley were appointed by the Board to serve as directors of the Company.”
Angela S. Lalor was appointed as Director at Enovis CORP.
“In connection with the vacancies created by the director resignations and retirement, on April 4, 2022, effective upon consummation of the Separation, each of Barbara W. Bodem, Angela S. Lalor, Dr. Christine Ortiz and Brady R. Shirley were appointed by the Board to serve as directors of the Company.”
Barbara W. Bodem was appointed as Director at Enovis CORP.
“In connection with the vacancies created by the director resignations and retirement, on April 4, 2022, effective upon consummation of the Separation, each of Barbara W. Bodem, Angela S. Lalor, Dr. Christine Ortiz and Brady R. Shirley were appointed by the Board to serve as directors of the Company.”
Thomas S. Gayner resigned as Director at Enovis CORP.
“Also, as previously announced, on March 31, 2022, Thomas S. Gayner resigned from the Board.”
Didier Teirlinck resigned as Director at Enovis CORP.
“On April 4, 2022, effective upon consummation of the Separation, each of Patrick W. Allender, Rhonda L. Jordan and Didier Teirlinck resigned from the board of directors of the Company (the “ Board ”) to serve on the board of directors of ESAB.”
Rhonda L. Jordan resigned as Director at Enovis CORP.
“On April 4, 2022, effective upon consummation of the Separation, each of Patrick W. Allender, Rhonda L. Jordan and Didier Teirlinck resigned from the board of directors of the Company (the “ Board ”) to serve on the board of directors of ESAB.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.